Cara Therapeutics

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Cara Therapeutics reports solid Q4 earnings amidst growth opportunities

Cara Therapeutics showcased strong revenue growth and positive feedback on KORSUVA injection sales in Q4 2022.
While facing challenges such as demand instability and regulatory uncertainties, the company remains confident in its growth prospects.
Strategic investments, milestone anticipation, and financial stability position Cara well for future value creation and market expansion.

Cara Therapeutics reports strong Q1 revenue, optimistic about pipeline growth

Cara Therapeutics delivered solid revenue in Q1 2023 driven by the successful launch of KORSUVA and Kapruvia. While facing increased operating expenses, the company remains optimistic about its pipeline's potential. Strategic focus on KORSUVA's success and ongoing R&D efforts position Cara for future growth.

Cara Therapeutics reports solid Q2 earnings amidst regulatory uncertainties

Cara Therapeutics posted strong financial performance in Q2 2023, driven by robust net sales and cash reserves, with a focus on maximizing shareholder value.
The company faces challenges related to potential CMS changes and European market dynamics but sees opportunities in international expansion and regulatory engagement.
Overall, Cara Therapeutics remains optimistic about the commercial prospects of its key products and pipeline, aiming for sustained growth and market leadership.

Cara Therapeutics extends cash runway, faces funding challenges ahead

Cara Therapeutics reports strong financials with extended cash runway. Progress in late-stage programs and successful monetization of royalties. Facing challenges with funding limitations and uncertainties around data releases.

Cara Therapeutics extends cash runway to 2026 amidst revenue challenges

Cara Therapeutics strategically focused on NP and oral DSK programs to drive growth.
Strong demand for KORSUVA injection but challenges from reimbursement changes.
Confidence in NP program and potential partnerships signal future opportunities.
Financially extended runway to 2026 but facing liquidity challenges with $1.8 million cash.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 11:15 a.m. ET.

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalysts to help unlock value.

Cara Therapeutics: De-Risked And Extremely Attractive

KORSUVA receives TDAPA reimbursement beginning April 2022

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, President and Chief Executive Officer, Thomas Reilly, Chief Financial Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The fireside chat will be available beginning Monday, November 22, 2021 at 10:00 a.m. ET.

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2021 Results - Earnings Call Transcript

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) –

Cara Therapeutics Reports Third Quarter 2021 Financial Results

Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Cara Therapeutics Announces CEO Transition

Enanta Pharmaceuticals

Ocugen, Inc.

These biotech stocks have recently been responsible for a slew of rocketship emojis.

3 Explosive Biotech Stocks -- Could They Shoot Even Higher?

STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 8, 2021 at 4:30 p.m. ET to report third quarter 2021 financial results and provide a corporate update.

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

STAMFORD, Conn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from the KARE Phase 2 clinical trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients. Results were presented by Brian Kim, MD, Associate Professor of Dermatology and Co-Director of the Center for the Study of Itch and Sensory Disorders at Washington University School of Medicine, during the Late Breaking News session of the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 2, 2021.

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus to be presented Results from KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus to be presented

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.20 p.m. ET.

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

There's good news at long last for the beaten-down biotech stock.

Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval

Ascendis Pharma

Jazz Pharmaceuticals

Sesen Bio Inc.

Sanofi

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

The biotech gets an important nod from a top regulator.

Why Cara Therapeutics Shot Higher Today

Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA. The post CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today appeared first on InvestorPlace.

CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today

Care Therapeutics Inc (NASDAQ:CARA) is seeing a influx of options activity today, following news that the U.S. Food and Drug Administration (FDA) approved its Korsuva difelikefalin injection to treat moderate-to-severe itching in adult patients with chronic kidney disease undergoing dialysis.

Biotech Stock Takes on Technical Ceiling After FDA Okay

CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

CARA Drug Wins FDA Nod for Pruritus Associated With CKD

Cara Therapeutics Inc (NASDAQ: CARA) is trading higher Tuesday after the company, and Vifor Pharma, announced the U.S. Food and Drug Administration approved KORSUVA for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. KORSUVA injection is a kappa opioid receptor agonist that targets the body's peripheral nervous system.

Why Is Cara Therapeutics Stock Trading Higher Today?

The FDA has approved Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma AG's Korsuva (difelikefalin) injection for severe-to-moderate pruritis (itching) in patients with chronic kidney disease (CKD) undergoing dialysis. Difelikefalin is an opioid agonist that targets the kappa opioid receptor in the peripheral nervous system.

See Why Cara Therapeutics (CARA) Stock Is Moving Higher On Tuesday

The shares of Cara Therapeutics Inc (NASDAQ: CARA) increased by over 20% pre-market. This is why it happened.

Cara Therapeutics Shares Increase Over 20% Pre-Market: Why It Happened

ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Cara Therapeutics (Nasdaq:CARA) today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. KORSUVA™ injection is a first-in-class kappa opioid receptor (KOR) agonist that targets the body's peripheral nervous system. The KOR

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Palo Alto Networks

After a record-setting day, the news for these two companies was icing on the cake.

These 2 Stocks Just Soared After Hours Monday

STAMFORD, Conn. and ST. GALLEN, Switzerland, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis . KORSUVA™ injection is a first-in-class kappa opioid receptor (KOR) agonist that targets the body's peripheral nervous system. The KORSUVA™ injection new drug application (NDA) received Priority Review by the FDA, which is granted to therapies that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

News for Cara Therapeutics Stock (CARA)